Kesimpta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0013/G 
This was an application for a group of variations. 
18/01/2024 
SmPC and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
data 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
IAIN/0016 
B.II.b.1.a - Replacement or addition of a 
04/01/2024 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0014 
B.II.b.1.z - Replacement or addition of a 
21/11/2023 
n/a 
manufacturing site for the FP - Other variation 
PSUSA/10927
Periodic Safety Update EU Single assessment - 
26/10/2023 
n/a 
PRAC Recommendation - maintenance 
/202303 
ofatumumab 
PSUSA/10927
Periodic Safety Update EU Single assessment - 
14/04/2023 
n/a 
PRAC Recommendation - maintenance 
/202209 
ofatumumab 
IB/0010 
C.I.11.z - Introduction of, or change(s) to, the 
15/03/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0006 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
09/02/2023 
22/09/2023 
SmPC 
new quality, preclinical, clinical or pharmacovigilance 
data 
IAIN/0011 
B.II.b.2.c.1 - Change to importer, batch release 
13/01/2023 
22/09/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10927
Periodic Safety Update EU Single assessment - 
27/10/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
ofatumumab 
IB/0008 
B.I.a.2.a - Changes in the manufacturing process of 
21/10/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
II/0007 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
20/10/2022 
22/09/2023 
SmPC 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/10927
Periodic Safety Update EU Single assessment - 
05/05/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
ofatumumab 
IB/0004/G 
This was an application for a group of variations. 
22/03/2022 
24/05/2022 
SmPC and PL 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0002 
B.I.c.2.c - Change in the specification parameters 
02/11/2021 
n/a 
and/or limits of the immediate packaging of the AS - 
Deletion of a non-significant specification parameter 
(e.g. deletion of an obsolete parameter) 
IA/0001 
A.6 - Administrative change - Change in ATC 
12/05/2021 
24/05/2022 
SmPC 
Code/ATC Vet Code 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4/4 
 
 
 
 
 
 
 
